Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24848855 | 0.88 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209368 | 0.88 | JAK2 (0.44) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423909 | 0.88 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL26233576 | 0.86 | JAK2 (0.41) | JAK2JAK1TYK2JAK3KDM4E | |
| SCHEMBL24849279 | 0.80 | JAK2 (0.36) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25271797 | 0.80 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25230751 | 0.80 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25227147 | 0.79 | CD274 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL24849259 | 0.76 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209340 | 0.75 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002376-A1 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002376-A1 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | JAK2 181/4885JAK1 331/4885TYK2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.